Autolus Therapeutics are further expanding their operations at the Cell and Gene Therapy Catapult (CGT Catapult) manufacturing centre, and are collaborating with CGT Catapult to achieve licensure for the commercial manufacture of their CAR-T cell therapies. This collaboration facilitates the company’s plans to manufacture CAR-T cell therapies for both clinical and commercial supply and the CGT Catapult and associated UK supply chain will gain new capability and expertise, adding to the favorable cell and gene therapy ecosystem in the UK.
Autolus are a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. They are one of five collaborators to have established their large-scale manufacturing operations at the CGT Catapult manufacturing centre in Stevenage, UK.
The facility, which has recently doubled in capacity, provides infrastructure, expertise and a surrounding cell and gene therapy ecosystem which is favorable for the growth of companies moving towards clinical adoption. Autolus are expanding within the facility to utilize additional cleanroom space in the newly operational modules, supporting the manufacture of materials for their pipeline products.
“We are proud to undertake this collaboration with Autolus, a pioneering company that has been showing tremendous progress with their pipeline products for oncology. We look forward to working with Autolus to meet all of the standards required for commercial CAR-T cell therapy manufacturing,” Matthew Durdy, CEO, Cell and Gene Therapy Catapult said. “With its unique operating model, the Manufacturing Centre is well suited as an international base for manufacturing innovation at scale and, having recently expanded, has the capacity to support new and existing collaborating companies as they grow.”